Arvinas (ARVN) Competitors $7.74 -0.07 (-0.90%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$7.77 +0.03 (+0.39%) As of 09/12/2025 05:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ARVN vs. IBRX, DNLI, OCUL, BLTE, AGIO, IRON, ARQT, ANIP, HRMY, and IDYAShould you be buying Arvinas stock or one of its competitors? The main competitors of Arvinas include ImmunityBio (IBRX), Denali Therapeutics (DNLI), Ocular Therapeutix (OCUL), Belite Bio (BLTE), Agios Pharmaceuticals (AGIO), Disc Medicine (IRON), Arcutis Biotherapeutics (ARQT), ANI Pharmaceuticals (ANIP), Harmony Biosciences (HRMY), and IDEAYA Biosciences (IDYA). These companies are all part of the "pharmaceutical products" industry. Arvinas vs. Its Competitors ImmunityBio Denali Therapeutics Ocular Therapeutix Belite Bio Agios Pharmaceuticals Disc Medicine Arcutis Biotherapeutics ANI Pharmaceuticals Harmony Biosciences IDEAYA Biosciences Arvinas (NASDAQ:ARVN) and ImmunityBio (NASDAQ:IBRX) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, dividends, risk, profitability, analyst recommendations, media sentiment, earnings and institutional ownership. Do insiders and institutionals hold more shares of ARVN or IBRX? 95.2% of Arvinas shares are owned by institutional investors. Comparatively, 8.6% of ImmunityBio shares are owned by institutional investors. 4.7% of Arvinas shares are owned by insiders. Comparatively, 76.8% of ImmunityBio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Which has more risk & volatility, ARVN or IBRX? Arvinas has a beta of 2.38, indicating that its share price is 138% more volatile than the S&P 500. Comparatively, ImmunityBio has a beta of 0.3, indicating that its share price is 70% less volatile than the S&P 500. Do analysts prefer ARVN or IBRX? Arvinas presently has a consensus target price of $19.76, suggesting a potential upside of 155.34%. ImmunityBio has a consensus target price of $10.75, suggesting a potential upside of 313.46%. Given ImmunityBio's stronger consensus rating and higher possible upside, analysts clearly believe ImmunityBio is more favorable than Arvinas.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arvinas 0 Sell rating(s) 10 Hold rating(s) 12 Buy rating(s) 0 Strong Buy rating(s) 2.55ImmunityBio 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20 Is ARVN or IBRX more profitable? Arvinas has a net margin of -19.47% compared to ImmunityBio's net margin of -648.57%. ImmunityBio's return on equity of 0.00% beat Arvinas' return on equity.Company Net Margins Return on Equity Return on Assets Arvinas-19.47% -12.01% -6.97% ImmunityBio -648.57%N/A -113.86% Does the media favor ARVN or IBRX? In the previous week, ImmunityBio had 2 more articles in the media than Arvinas. MarketBeat recorded 8 mentions for ImmunityBio and 6 mentions for Arvinas. Arvinas' average media sentiment score of 1.59 beat ImmunityBio's score of 0.54 indicating that Arvinas is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arvinas 4 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive ImmunityBio 0 Very Positive mention(s) 4 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger valuation and earnings, ARVN or IBRX? Arvinas has higher revenue and earnings than ImmunityBio. Arvinas is trading at a lower price-to-earnings ratio than ImmunityBio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArvinas$372.80M1.52-$198.90M-$1.01-7.66ImmunityBio$14.74M166.74-$413.56M-$0.48-5.42 SummaryImmunityBio beats Arvinas on 9 of the 17 factors compared between the two stocks. Get Arvinas News Delivered to You Automatically Sign up to receive the latest news and ratings for ARVN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ARVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARVN vs. The Competition Export to ExcelMetricArvinasMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$573.40M$3.19B$5.85B$10.14BDividend YieldN/A2.30%5.68%4.60%P/E Ratio-7.6621.4375.3425.98Price / Sales1.52429.44514.54181.13Price / CashN/A46.6837.5660.44Price / Book0.959.6112.156.29Net Income-$198.90M-$53.29M$3.29B$271.07M7 Day Performance-1.15%0.13%0.74%3.87%1 Month Performance9.17%5.61%4.82%4.88%1 Year Performance-69.10%10.49%60.58%26.12% Arvinas Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARVNArvinas3.0067 of 5 stars$7.74-0.9%$19.76+155.3%-68.4%$573.40M$372.80M-7.66420Positive NewsIBRXImmunityBio2.5077 of 5 stars$2.41+0.4%$10.75+346.1%-25.5%$2.28B$56.60M-5.02590Analyst ForecastDNLIDenali Therapeutics4.374 of 5 stars$15.50+0.5%$33.62+116.9%-49.2%$2.27B$330.53M-5.54430Positive NewsOCULOcular Therapeutix3.9358 of 5 stars$12.71-6.5%$17.20+35.3%+47.1%$2.21B$63.72M-9.93230Positive NewsBLTEBelite Bio2.606 of 5 stars$67.51+2.7%$96.67+43.2%+42.7%$2.15BN/A-43.5510News CoveragePositive NewsGap UpAGIOAgios Pharmaceuticals4.3256 of 5 stars$36.41+1.1%$56.00+53.8%-18.1%$2.12B$36.50M3.31390Insider TradeIRONDisc Medicine3.2525 of 5 stars$61.91+1.9%$98.30+58.8%+23.9%$2.11BN/A-13.8530Positive NewsARQTArcutis Biotherapeutics2.4296 of 5 stars$17.33+1.0%$19.80+14.3%+64.4%$2.08B$196.54M-23.11150Insider TradeANIPANI Pharmaceuticals4.0326 of 5 stars$95.20-0.2%$88.25-7.3%+74.0%$2.07B$614.38M-123.63600Positive NewsHRMYHarmony Biosciences4.6079 of 5 stars$35.83-0.4%$51.00+42.3%-14.2%$2.06B$714.73M11.56200Positive NewsIDYAIDEAYA Biosciences3.9802 of 5 stars$23.39-13.9%$45.77+95.7%-31.8%$2.05B$7M-6.1780Trending NewsAnalyst ForecastAnalyst RevisionHigh Trading Volume Related Companies and Tools Related Companies IBRX Competitors DNLI Competitors OCUL Competitors BLTE Competitors AGIO Competitors IRON Competitors ARQT Competitors ANIP Competitors HRMY Competitors IDYA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ARVN) was last updated on 9/13/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arvinas, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arvinas With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ARVN Stock Alerts